Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):36–44. doi: 10.1097/QAI.0000000000000245

Figure 1.

Figure 1

Mean fold-change (95% confidence interval) in urine protein:creatinine ratio (panels A and B) and urine albumin: creatinine ratio (panels C and D) among 245 participants randomized to initiate antiretroviral therapy in A5224s. Mean fold-change in each ratio is compared between participants randomized to abacavir/ lamivudine versus TDF/ emtricitabine (A and C) and between participants randomized to open-label EFV versus ATV/ ritonavir (B and D). Data are presented through week 192 for descriptive purposes; comparative statistics were performed at week 48 and week 96. *two-sample t-test.